Avita Medical NASDAQ: RCEL raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound treatment system and growing adoption of Cohealyx.
Avita Medical shows an emerging operational inflection, with revenue rising 17.8% year over year to a record $21.7M in 2026Q2 and the operating loss narrowing to $6.9M — its smallest across ten quarters — helped by SG&A falling to $19.5M from $24.7M in 2024Q3.
Price trend, volume and key moving averages
Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.20+16.5% vs -$0.24 | $26M+16.8% vs $22M |
Q3 2026 Aug 6, 2026 | -$0.25+14.6% vs -$0.29 | $21M+6.1% vs $20M |
Q2 2026 May 14, 2026 | -$0.35+0.0% vs -$0.35 | $19M+5.2% vs $18M |
Q1 2026 Feb 12, 2026 | -$0.38-4.3% vs -$0.36 | $17M-2.3% vs $18M |
Avita Medical NASDAQ: RCEL raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound treatment system and growing adoption of Cohealyx.
Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30, 2026.
CMS finalizes nationally published physician valuations; CMS's four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized national physician valuations for skin cell suspension autograft (SCSA) procedures performed using RECELL® under the Calendar Year 2027 Medicare Physician Fee Schedule.
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026.
Benchmark RCEL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Avita Medical Inc. (RCEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.22 | $378.11M | -13.01 | 11.45% | -42.65% | — | — | |
| $0.22 | $30.86M | 7.33 | 14.21% | -15.92% | -36.21% | — | |
| $0.76 | $34.07M | -1.05 | 15.84% | -53.57% | — | — | |
| $3.18 | $463.52M | -24.16 | 19.99% | -6.32% | -8.29% | — | |
| $11.30 | $1.31B | -10.84 | 8.28% | -16.78% | -35.81% | — | |
| $2.65 | $111.59M | -14.02 | 9.86% | -14.16% | -68.79% | — |
Avita Medical Inc. (RCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Avita Medical Inc. (RCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 5, 2026·SEC
Nov 2, 2026·SEC
Aug 11, 2026·SEC
Get notified when RCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Avita Medical Inc. (RCEL) stock FAQ — growth, dividends, profitability & financials explained
Avita Medical Inc. (RCEL) reported $84.7M in revenue over the trailing twelve months. Revenue was $71.6M in fiscal year 2025.
Avita Medical Inc. (RCEL) grew revenue by 17.0% over the trailing twelve months, compared with the twelve months before.
No. Avita Medical Inc. (RCEL) reported a net loss of $36.1M over the trailing twelve months.
Avita Medical Inc. (RCEL) had negative free cash flow of $18.2M over the trailing twelve months.